Long terminal repeat (LTR) of human immunodeficiency virus (HIV) type 1 is activated by thyroid hormone (T3) receptor ␣ (T3R␣) in the absence of ligand. Addition of T3 reverses this effect. This activity is mediated by a high affinity T3 response element (T3RE) within the HIV-1 LTR, termed the HIV-T3RE (bases ؊74 to ؊50), which coincides with the Sp1 element as demonstrated by mobility shift, DNaseI footprinting, and methylation interference analyses. HIV-T3RE mediates ligand-independent activation of transcription by T3R␣ when linked to a heterologous promoter. In addition, the viral transactivator Tat synergizes with T3R␣ to activate the HIV-1 LTR in the absence of T3, which is relieved in its presence. These findings have implications for the possible control of HIV-1 LTR activity by T3.
Long terminal repeat (LTR) of human immunodeficiency virus (HIV) type 1 is activated by thyroid hormone (T3) receptor ␣ (T3R␣) in the absence of ligand.
Addition of T3 reverses this effect. This activity is mediated by a high affinity T3 response element (T3RE) within the HIV-1 LTR, termed the HIV-T3RE (bases ؊74 to ؊50), which coincides with the Sp1 element as demonstrated by mobility shift, DNaseI footprinting, and methylation interference analyses. HIV-T3RE mediates ligand-independent activation of transcription by T3R␣ when linked to a heterologous promoter. In addition, the viral transactivator Tat synergizes with T3R␣ to activate the HIV-1 LTR in the absence of T3, which is relieved in its presence. These findings have implications for the possible control of HIV-1 LTR activity by T3.
HIV-1
1 gene expression is regulated by binding and interplay of both viral and cellular host proteins to the HIV-1 LTR (see Refs. 1 and 2). The HIV-1 LTR extends from Ϫ454 to ϩ184 and can be divided into three regions based on the general effect of each region on HIV-1 gene expression: the modulatory element extending from Ϫ454 to Ϫ78, the core region, from Ϫ78 to Ϫ1, and the TAR element, from ϩ1 to ϩ60 (1, 2). The modulatory region contains elements that bind a variety of cellular factors including AP-1, chicken ovalbumin upstream promoter transcription factor, nuclear factor of activated T cells, upstream stimulatory factor, T-cell factor-1␣, nuclear factor -B (NF-B), and some members of the nuclear receptor superfamily (Refs. 1, 2, 3, and references therein). The core element is required for both basal and Tat-induced gene expression and it interacts with the transcription factor Sp1 and TFIID. The TAR element, which is critical for Tat activation of the HIV-1 LTR binds Tat and several cellular factors.
Multiple endocrine abnormalities occur in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC). Two recent studies (4, 5) have found that serum thyroid hormone (T3) levels are frequently altered in patients with AIDS and ARC, with the most frequent alterations being low serum T3 levels and free T3 indexes and high thyronine-binding globulin levels. These are correlated with survival rate. However, molecular mechanisms underlying this correlation have not been determined.
The biological actions of T3 are mediated by nuclear receptors (T3Rs), which convert the signals generated by T3 binding into changes in transcription of target genes (for a review see Ref. 6 ). T3Rs are encoded by the c-ErbA␣ and c-ErbA␤ genes (7, 8) . These proteins belong to the superfamily of nuclear receptors, which are ligand-activated transcription factors related in their highly conserved DNA binding domain and relatively well conserved ligand binding domain (9, 10) . T3Rs recognize a consensus half-site, which can be arranged as a palindrome, a direct, or an inverted repeat in which the exact sequence of both the half-site and the spacer affect receptor-specific recognition (11) (12) (13) . Although in most cases T3Rs are ligand-activated transactivators, ligand-independent activation by T3Rs has recently been documented (14, 15) . One of the T3REs that mediates this ligand-independent activation has been characterized and shown to consist of an inverted repeat of an altered half-site with 6-bp spacing (14) .
In light of consistent alterations in T3 levels in patients with AIDS and ARC (4, 5), we determined whether T3Rs and T3 affect HIV-1 LTR activity. We found that T3R␣ activates the HIV-1 LTR in the absence of T3, which is lost with the addition of T3. This activity is mediated by binding of T3R␣ to a high affinity T3RE, which overlaps the Sp1 element. Furthermore, T3R␣ synergizes with Tat in the absence of T3, but this is lost in the presence of T3. These findings suggest that T3 and T3R␣ may have a role in the regulation of HIV-1 LTR activity.
MATERIALS AND METHODS
Plasmids-The HIV-1-CAT (pILIC-CAT; Ref. 16 ), 2XT3RE-LUC (17) , and MHC-CAT (18) reporters have been previously described. Expression vectors for T3R␣ (14) and Tat (19) were also described previously.
To obtain Ϫ60 Col HIV-T3RE-LUC, a double-stranded oligonucleotide corresponding to bases Ϫ85 to Ϫ45 of the HIV-1 LTR with HindIII and SalI sites on the 5Ј and 3Ј ends, respectively, was inserted into Ϫ60 Col-LUC (14) between the HindIII and SalI sites.
Cell Culture and Transfection Assays-CV1 cells were routinely maintained in Dulbecco's modified Eagle's medium supplemented with 5% bovine calf serum. Cells were transfected by the calcium phosphate coprecipitation method. For a 60-mm dish, transfected DNA included 1 g of reporter DNA, 1 g of expression vector, and pUC18 to a total of 3 g of DNA. 6 -8 h later, cells were washed with phosphate-buffered saline and then maintained in Dulbecco's modified Eagle's medium supplemented with 0.5% bovine calf serum in the presence or absence of 10 Ϫ7 M T3. Cells were harvested 36 h later, and CAT or luciferase activities were determined as described (20, 21) .
Mobility Shift Analyses-32 P-labeled DNA probes were incubated with recombinant T3R␣ expressed in Escherichia coli as described previously (14) . Supershift analysis with T3R␣-specific antiserum was carried out as described before (14) . For heterodimerization experi-ments with retinoid X receptor ␣ (RXR␣), recombinant RXR␣ made in E. coli as a glutathione S-transferase fusion protein (22) was mixed with recombinant T3R␣ and incubated at room temperature for 10 min. The rest of the mobility shift mixture was added, and incubation was continued for an additional 10 min before loading on the gel.
DNase I Footprinting-DNase I footprinting assays were done with 1-2 ng of 32 P-labeled TaqI-HindIII fragment of the HIV-1 LTR. The probe was generated by restriction digest of the HIV-1 LTR with TaqI, by end-labeling on the TaqI site with reverse transcriptase, and by subsequent digestion with HindIII and purification of the TaqI-HindIII fragment. The binding reaction was as described above for mobility shift assays. However, after the 10-min incubation, 1 mM CaCl 2 was added, and the reaction mixture was incubated for a further 2 min at room temperature. Increasing concentrations of DNase I were then added, and incubation continued for 1-2 more minutes. Reaction was terminated by adding 2 ϫ volume of stop-buffer (200 mM NaCl, 20 mM EDTA, 1% SDS, 50 g/ml tRNA) followed by immediate freezing in liquid nitrogen. Samples were thawed, extracted with phenol/chloroform, and ethanol-precipitated. Pellets were resuspended in 1 l of water and 1.5 l of formamide loading buffer (80% formamide, 20 mM EDTA, 0.025% bromphenol blue, and 0.025% xylene-cyanol) and boiled for 3 min prior to loading on a standard 8% sequencing gel. The gel was dried and exposed to x-ray film at Ϫ80°C with an intensifying screen.
Methylation Interference Assay-This assay was performed as described previously (23) . Single-stranded oligonucleotides were end-labeled with [␥-32 P]ATP using T4 polynucleotide kinase and annealed to their daughter strands. The double-stranded oligonucleotides were partially methylated using dimethylsulfate, and preparative mobility shift assays were performed with the methylated probes. Free and shifted complexes were electrotransferred onto DEAE-81 paper, visualized by autoradiography, and recovered. The methylated residues were cleaved with 1 M piperidine at 90°C for 30 min, lyophilized, and resuspended in 1 l of water and 1.5 l of formamide loading buffer. The samples were resolved on a standard 12% sequencing gel, dried, and exposed to x-ray film at Ϫ80°C with an intensifying screen. Half-maximal inhibition of T3R␣-mediated activation of HIV-1-CAT expression by T3 occurred at 4 ϫ 10 Ϫ9 M T3, and maximal inhibition was achieved at 10 Ϫ7 M (Fig. 1B) . These concentrations were similar to those required for half-maximal T3-dependent activation of a 2XT3RE-LUC reporter (17) , which has two copies of the consensus T3RE driving expression of the luciferase gene, or the relief of ligand-independent activation of the RSV 180 LUC reporter (14) .
RESULTS

Ligand-independent Activation of HIV-1 LTR by T3R␣-To
High Affinity Binding Site for T3R␣ within the HIV-1 LTRRecently, we have identified a unique T3RE found in the Rous sarcoma virus (RSV) LTR, called the RSV-T3RE, to which T3R␣ binds and activates transcription in a ligand-independent manner (14) . Upon scanning the HIV-1 LTR, we did not find any sequences matching or similar to that of the RSV-T3RE. To determine whether T3R␣ binds to another sequence within the HIV-1 LTR, we used the mobility shift assay. HIV-1 LTR was digested at the TaqI site (Ϫ117), and the 318-bp AvaII-TaqI and 195-bp TaqI-HindIII fragments were used as probes in the mobility shift assay ( Fig. 2A) . Although both fragments specifically bound recombinant T3R␣ produced in E. coli, as demonstrated by the complete competition of binding by 50 ϫ molar excess of unlabeled probe, binding to the TaqIHindIII fragment was approximately 20-fold stronger, which was analyzed further (Fig. 2B) . The mobility of bound TaqIHindIII probe was decreased upon incubation with a T3R␣-specific antiserum but not with nonimmune serum, demonstrating the presence of T3R␣ in the shifted band (Fig. 2C) .
We next used DNase I footprinting to study this interaction in greater detail (Fig. 3A) . TaqI-HindIII (bases Ϫ117 to ϩ78) fragment of the HIV-1 LTR was end-labeled with 32 P and used as probe in the DNase I footprinting assay. Incubation of the probe with increasing amounts of T3R␣ gave rise to a major protected region spanning nucleotides Ϫ74 to Ϫ50 compared with control reactions containing bovine serum albumin. A region of light protection was also observed downstream of this footprint. However, this region was not important for binding of T3R␣ in the methylation interference assay (see below) and thus may represent nonspecific or weak interactions.
To further characterize the interaction of T3R␣ with the HIV-1 LTR, the methylation interference technique was used (23) . This procedure identifies guanine residues that prevent or weaken binding of a factor when methylated. When an oligonucleotide corresponding to Ϫ84 to Ϫ46 of the HIV-1 LTR, termed the HIV-T3RE, was labeled on the coding strand and used as probe, six bands corresponding to guanines at positions Ϫ70, Ϫ69, Ϫ64, Ϫ61, Ϫ60, and Ϫ59 were dramatically reduced in intensity in complexes formed by T3R␣ (Fig. 3B) . When the same oligonucleotide labeled on the noncoding strand was used, methylation of four guanine residues at positions Ϫ68, Ϫ67, Ϫ62, and Ϫ57 were found to suppress T3R␣ binding. These results are summarized in Fig. 3C along with the boundaries of the DNase I footprint.
The HIV-T3RE was also used in the mobility shift assay to conclusively demonstrate T3R␣ binding. Fig. 4A shows that incubation of the 32 P-labeled HIV-T3RE with recombinant T3R␣ resulted in a complex with decreased mobility. The formation of this complex was specific since it was greatly decreased and then abolished in the presence of 4-and 10-fold molar excess, respectively, of unlabeled HIV-T3RE. The presence of T3R␣ in the shifted band was directly demonstrated by its disappearance and the formation of a supershifted band in the presence of T3R␣-specific antiserum but not in the presence of nonimmune serum.
We next compared the affinity of T3R␣ for the HIV-T3RE and a previously characterized T3RE derived from the myosin heavy chain (MHC) promoter (MHC-T3RE) (24) . Recombinant T3R␣ was incubated with 32 P-labeled HIV-T3RE either alone or in the presence of increasing amounts of unlabeled HIV-T3RE or MHC-T3RE. Fig. 4B shows that comparable amounts of either oligonucleotide interfered with T3R␣ binding to the HIV-T3RE probe, with half-maximal inhibition occurring at approximately 4-fold excess of unlabeled oligonucleotide. Thus, T3R␣ binds to the HIV-T3RE with a similar affinity as the MHC-T3RE.
HIV-T3RE Is Sufficient for Mediating Ligand-independent Activation by T3R␣-To assess whether the HIV-T3RE by itself is capable of mediating ligand-independent activation by T3R␣, a single copy of the HIV-T3RE oligonucleotide was placed in front of a deletion derivative of the collagenase promoter fused to the luciferase reporter gene, Ϫ60 Col-LUC (14) . This construct, Ϫ60 Col HIV-T3RE-LUC, was cotransfected into CV-1 cells with a T3R␣ expression vector, and luciferase activities in Plabeled TaqI-HindIII fragment of the HIV-1 LTR was used in a mobility shift assay with 30 ng of recombinant T3R␣ as described above. Binding reactions contained no T3R␣, only T3R␣, anti-T3R␣ antiserum (␣-cErbA␣), T3R␣ plus anti-T3R␣ antiserum (␣-c-ErbA␣), or T3R␣ plus nonimmune rabbit serum (NRS) as indicated. SS represents the migration position of the antibody supershifted complex.
FIG. 3. Delineation of the T3RE on the HIV-1 LTR.
A, DNase I footprinting was performed as described under "Materials and Methods" using the TaqI-HindIII fragment of HIV-1 LTR that was 32 Plabeled on the noncoding strand. The amounts of recombinant T3R␣ (c-ErbA␣) used in the reactions are indicated at the top. As a control 1.5 g of bovine serum albumin (BSA) was used in parallel reactions. The G ϩ A ladder is shown on the left and the nucleotides corresponding to the region of the footprint are indicated. B, methylation interference was performed as described under "Materials and Methods" using an oligonucleotide spanning Ϫ84/-45 of the HIV-1 LTR and recombinant T3R␣. The oligonucleotides were labeled on either the coding or noncoding strand, as indicated, and then used in the assay. F, free probe representing all cleaved guanines; B, probe bound to T3R␣. The guanines that when methylated decrease T3R␣ binding are indicated by arrows. C, summary of the footprinting experiments. The sequence of the HIV-1 LTR-spanning nucleotides Ϫ84 to Ϫ46 are shown. The guanines that when methylated interfere with T3R␣ binding are shown in boldface and indicated by stars. The protected region in the DNase I footprinting assay is shown by the bracket.
the absence and presence of T3 were determined. While Ϫ60 Col-LUC did not respond to T3R␣ in the absence or presence of T3, insertion of the HIV-T3RE resulted in approximately 7-fold activation by the cotransfected T3R␣ expression vector (Fig. 5) . This response was almost completely inhibited upon addition of T3. On the other hand, 2XT3RE-LUC expression was activated 12-fold only in the presence of T3.
RXR␣ Inhibits Binding of T3R␣ to the HIV-T3RE-DNA binding and ligand-dependent transactivation by T3R␣ is augmented by heterodimerization with RXRs (18, (25) (26) (27) (28) (29) (30) . We therefore assessed the effect of heterodimerization with RXR␣ on the ability of T3R␣ to bind to the HIV-T3RE. Recombinant T3R␣ produced in E. coli was first incubated with buffer or recombinant RXR␣ made in E. coli as a glutathione S-transferase fusion protein (22) to allow for heterodimer formation. This was then used in the mobility shift assay to assess binding to the HIV-T3RE and MHC-T3RE probes. As shown in Fig. 6 and consistent with data shown in Fig. 4B , in the absence of RXR␣, there was an approximately equal amount of binding to both T3REs. As expected, in the presence of RXR␣, a further shifted band that was greatly increased in intensity was observed with the MHC-T3RE corresponding to the T3R␣-RXR␣ heterodimers. In contrast, although heterodimers were formed on the HIV-T3RE, the total binding, including both homodimers and heterodimers, was dramatically decreased. Similar results were obtained when cell-free translated RXR␣ was used (data not shown). These results show that heterodimerization with RXR␣ affects T3R␣ binding to the HIV-T3RE in ways diametrically opposed to T3R␣ binding to the
MHC-T3RE.
Synergy between Viral Transactivator Tat and T3R␣-One of the critical regulatory proteins encoded by HIV-1 is Tat, which activates HIV-1 gene expression through its interaction with the TAR element (for a review, see Refs. 1 and 2). To determine whether there is a functional interaction between T3R␣ and Tat in the regulation of HIV-1 LTR activity, we used cotransfection experiments. The HIV-1-CAT reporter and expression vectors encoding T3R␣ and/or Tat were cotransfected into CV-1 cells. The cells were either left untreated or treated with T3, and CAT activities were determined. When expression vectors were used at levels that resulted in maximal HIV-1-CAT in- 
FIG. 6. Heterodimerization with RXR␣ interferes with T3R␣
binding to the HIV-T3RE. Recombinant T3R␣ produced in E. coli was incubated either alone or with recombinant GST-RXR␣ at room temperature for 10 min and then used in the mobility shift assay with 32 P-labeled HIV-T3RE or MHC-T3RE probes. C-C, T3R␣ homodimer; C-R, T3R␣/RXR␣ heterodimer; F, free probe. duction, no significant effect was observed (data not shown). However, when suboptimal levels of T3R␣ and Tat were used, a strong synergistic activation of HIV-1-CAT resulted, which was approximately 8-fold higher than the sum of T3R␣ and Tat activities separately (Fig. 7) . Interestingly, this synergism was lost in the presence of T3. DISCUSSION We have found that T3R␣ binds to and activates the HIV-1 LTR in the absence of T3. Addition of T3 reverses this effect. The T3R␣ binding site, termed the HIV-T3RE, overlaps with the Sp1 element, which is important for HIV-1 gene expression, viral replication, and infectivity (1, 2). Since T3R␣ is expressed in human mononuclear cells and human leukemic cell lines that can be infected by HIV-1 (31, 32) , the interplay of T3R␣ and Sp1 on the HIV-1 LTR may have important consequences for HIV-1 gene expression, replication, and infectivity.
Detailed by DNase I and methylation interference footprinting, the HIV-T3RE is the second example of a new type of hormone response element that is capable of mediating ligandindependent activation by T3R␣. The RSV-T3RE, found in the LTR of Rous sarcoma virus, has previously been characterized as the first example of such an element (14) . Unlike the classical T3REs, which have direct repeats of the half-site AG-GTCA with a 4-bp spacer, such as the MHC-T3RE, or a palindrome with no spacers, the RSV-T3RE is an inverted repeat of a related but distinct half-site AAGGCA with a 6-bp spacer (14) . HIV-T3RE, on the other hand, contains a single classical half-site AGGCCA on the noncoding strand between bases Ϫ66 and Ϫ71, but no other related sequence can be discerned either on the coding or the noncoding strands within the boundaries of the T3R␣ footprint. Instead, T3R␣ binds the sequence GGCGGG on the coding strand between bases Ϫ64 and Ϫ59, which is clearly not related to either the classical half-site or that found in the RSV-T3RE. Therefore, HIV-T3RE defines a new type of element that is distinct from all previously described T3REs.
We have investigated the relative affinity of T3R␣ binding to the HIV-T3RE compared with a classical T3RE from the MHC␣ promoter in a mobility shift assay. Oligonucleotide competition studies demonstrated that the HIV-T3RE is comparable in its affinity to the MHC-T3RE for T3R␣ binding (Fig. 4B) . This suggests that changes in the affinity for DNA binding is not a determinant for the unique activity of T3R␣ through the HIV-T3RE. Instead, different structural changes in T3R␣ when bound to the HIV-T3RE compared with the MHC-T3RE could be responsible for the differences observed in biological activities.
Since T3Rs heterodimerize with RXRs, which results in enhanced DNA binding as well as transactivation potential (18, (25) (26) (27) (28) (29) (30) , we investigated the effect of RXR␣ on DNA binding by T3R␣. Surprisingly, although heterodimerization with RXR␣ greatly increased binding of T3R␣ to the MHC-T3RE, as previously shown for other positively acting T3REs (18, (25) (26) (27) (28) (29) (30) , binding to the HIV-T3RE was significantly decreased. This suggests that the heterodimeric T3R␣-RXR␣ complex is not in a favorable conformation to bind to the HIV-T3RE. Thus, the majority of the T3R␣-mediated transactivation through the HIV-T3RE involves T3R␣ homodimers, and expression of RXR␣ is expected to decrease this activity.
A variety of well studied cis-acting regulatory sequences exist on the HIV-1 LTR, which interact with host derived cellular transcriptional factors that control viral gene expression (see Refs. 1 and 2). Of these, the Sp1 element located in the proximal promoter spanning bases Ϫ78 to Ϫ46 includes three binding sites for the host transcription factor Sp1 and plays an important role in HIV-1 LTR activity. HIV-T3RE substantially overlaps with the Sp1 element. Mixing of T3R␣ and Sp1 does not give rise to a ternary complex involving T3R␣, Sp1, and the HIV-T3RE, 2 which suggests that binding of Sp1 and T3R␣ to the HIV-T3RE is mutually exclusive. Therefore, T3R␣ is likely to interfere with Sp1 binding to the HIV-1 LTR, and this is expected to influence HIV-1 LTR activity.
Another factor that has a critical role in HIV-1 LTR activity, viral replication, and infectivity is the viral activator protein Tat. We found that T3R␣ synergizes with Tat to activate the HIV-1 LTR in the absence of T3. Addition of T3 abrogates this effect. The mechanism underlying this synergism is not clear at present. It has previously been shown that Tat can activate the HIV-1 LTR when fused to the DNA binding domain of a transcription factor, such as c-Jun or GAL4, provided that the appropriate response element is inserted upstream to the Sp1 sites in the HIV-1 LTR (33, 34). Therefore, it is possible that by interacting with T3R␣, which binds to the HIV-1 LTR, Tat can more readily participate in targeting the transcriptional machinery. For example, this may involve direct protein-protein interactions between T3R␣ and Tat. The details of the mechanism of this synergism remain to be studied.
Our findings differ from those recently reported by DesaiYajnik and Samuels (35) . These investigators found that T3R␣ interacted with several sites in the HIV-1 proximal promoter spanning both the Sp1 and NF-B elements determined by mobility shift analyses. Since footprinting data were not provided and comparisons were not made with already characterized T3REs for the relative affinity of these sites, it remains unclear as to which one of these sequences mediates the biological effect of T3R␣. DNase I and methylation interference footprinting data presented here clearly demonstrate the boundaries of the HIV-T3RE to be a single site overlapping the Sp1 element. Furthermore, comparison with the well established MHC-T3RE indicates that HIV-T3RE is a high affinity binding site for T3R␣. Desai-Yajnik and Samuels also found that deletion derivatives of the HIV-1 LTR are activated by T3R␣ in a ligand-dependent manner. In contrast we find that ligand binding relieves activation of the HIV-1 LTR by T3R␣. Since data with full-length HIV-1 LTR were not presented in these studies, we cannot directly compare their data with those 2 A. Rahman, unpublished data. presented here. However, the fact that HIV-T3RE can be linked to a heterologous promoter and mediate ligand-independent activation by T3R␣, which is relieved by T3 binding, supports our findings obtained with the full-length HIV-1 LTR.
Patients with AIDS or ARC exhibit multiple endocrine abnormalities (21, 36 -39) . In addition, serum thyroid hormone levels are frequently altered in these patients (4, 5) . Not only were the T3 index values low that best correlated with the hospital stay and outcome of the disease, but in all levels of illness there was an increase in the thyronine-binding globulin levels, which rose with the progression of HIV infection (4, 5). The findings described in the present study may provide a molecular explanation for these clinical findings. In the HIVinfected patient when the T3 levels are normal the HIV-1 LTR would be relieved of the constitutive activation by T3R␣, which would result in reduced viral transcriptional activity along with impaired replication and infectivity, relieving the symptoms. However, when the T3 levels drop, HIV-1 LTR would be efficiently activated by T3R␣, resulting in increased viral transcription, replication, and infectivity, which in turn would stimulate the progress of the disease. The validity of this hypothesis can be directly tested by assessing the effect of T3 on viral replication and infectivity. If the hypothesis is confirmed, replenishment of T3 levels may provide a nontoxic therapeutic approach to treatment of HIV-1 infection.
